Evaluation of the Humoral Response to Adeno-Associated Virus-Based Gene Therapy Modalities Using Total Antibody Assays

The number of viral vector-based gene therapies (GTx) continues to grow with two products (Zolgensma® and Luxturna®) approved in the USA as of March 2021. To date, the most commonly used vectors are adeno-associated virus-based (AAV). The pre-existing humoral immunity against AAV (anti-AAV antibodie...

Descripción completa

Detalles Bibliográficos
Autores principales: Gorovits, Boris, Azadeh, Mitra, Buchlis, George, Harrison, Travis, Havert, Mike, Jawa, Vibha, Long, Brian, McNally, Jim, Milton, Mark, Nelson, Robert, O’Dell, Mark, Richards, Karen, Vettermann, Christian, Wu, Bonnie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445016/
https://www.ncbi.nlm.nih.gov/pubmed/34529177
http://dx.doi.org/10.1208/s12248-021-00628-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445016/
https://www.ncbi.nlm.nih.gov/pubmed/34529177
http://dx.doi.org/10.1208/s12248-021-00628-3

Ejemplares similares